Compare Gitlab Inc (GTLB) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Heron Therapeutics Inc — how do they compare? Gitlab Inc trades at $55.09 (market cap $8.92B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: Gitlab Inc is far larger — about 131.2× Heron Therapeutics Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Heron Therapeutics Inc for 35 Days on average.
| GTLB | HRTX | |
|---|---|---|
Market Cap | $8.92B | $68.01M |
Volume | 4,716,893 | 1,891,941 |
Sector | Technology | Health |
52-Week High | $53.56 | $1.49 |
52-Week Low | $19.42 | $0.27 |
Typical Hold Time | 62 Days | 35 Days |
Enterprise Value | $7.66B | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $53.56, up 3.02% today and near its 52-week high, with strong technical momentum indicated by moving averages. The company shows impressive revenue growth, reaching $759 million in 2025, but remains unprofitable with a negative net income margin of -4.99%. Recent Q2 2026 earnings beat expectations, and the stock surged on raised guidance and AI-driven demand optimism.
Outlook: GitLab benefits from AI integration in software development and strong sales momentum, but high valuation multiples (P/E 521) and persistent losses pose risks. Analyst consensus is mixed with a $49.71 price target below current levels, suggesting cautious optimism amid execution challenges and competitive pressures.
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
